HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas.

Abstract
Glioblastoma is a devastating primary brain tumor resistant to conventional therapies. In this study, we tested the efficacy of combining temozolomide with curcumin, a phytochemical known to inhibit glioblastoma growth, and investigated the mechanisms involved. The data showed that synergy between curcumin and temozolomide was not achieved due to redundant mechanisms that lead to activating protective autophagy both in vitro and in vivo. Autophagy preceded apoptosis, and blocking this response with autophagy inhibitors (3-methyl-adenine, ATG7 siRNA and chloroquine) rendered cells susceptible to temozolomide and curcumin alone or combinations by increasing apoptosis. While curcumin inhibited STAT3, NFκB and PI3K/Akt to affect survival, temozolomide-induced autophagy relied on the DNA damage response and repair components ATM and MSH6, as well as p38 and JNK1/2. However, the most interesting observation was that both temozolomide and curcumin required ERK1/2 to induce autophagy. Blocking this ERK1/2-mediated temozolomide and curcumin induced autophagy with resveratrol, a blood-brain barrier permeable drug, improved temozolomide/curcumin efficacy in brain-implanted tumors. Overall, the data presented demonstrate that autophagy impairs the efficacy of temozolomide/curcumin, and inhibiting this phenomenon could provide novel opportunities to improve brain tumor treatment.
AuthorsAlfeu Zanotto-Filho, Elizandra Braganhol, Karina Klafke, Fabrício Figueiró, Sílvia Resende Terra, Francis Jackson Paludo, Maurílio Morrone, Ivi Juliana Bristot, Ana Maria Battastini, Cassiano Mateus Forcelini, Alexander James Roy Bishop, Daniel Pens Gelain, José Cláudio Fonseca Moreira
JournalCancer letters (Cancer Lett) Vol. 358 Issue 2 Pg. 220-231 (Mar 28 2015) ISSN: 1872-7980 [Electronic] Ireland
PMID25542083 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Dacarbazine
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Curcumin
  • Temozolomide
Topics
  • Animals
  • Apoptosis (drug effects)
  • Autophagy (drug effects)
  • Brain Neoplasms (drug therapy, metabolism)
  • Cell Cycle Checkpoints (drug effects)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Curcumin (pharmacology)
  • Dacarbazine (analogs & derivatives, pharmacology)
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Glioblastoma (drug therapy, metabolism)
  • Humans
  • Male
  • Mitogen-Activated Protein Kinase 1 (metabolism)
  • Mitogen-Activated Protein Kinase 3 (metabolism)
  • Rats
  • Temozolomide

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: